Minimal residual disease: a target for radioimmunotherapy with 131I-labeled monoclonal antibodies? Some dosimetric considerations

Recent Results Cancer Res. 1996:141:67-75. doi: 10.1007/978-3-642-79952-5_5.

Authors

M L Sautter-Bihl¹, G Herbold, H Bihl

Affiliation

¹ Department of Radiooncology and Nuclear Medicine, Klinikum Karlsruhe, Germany.

PMID: 8722420
DOI: 10.1007/978-3-642-79952-5_5

No abstract available

MeSH terms

Absorption
Antibodies, Monoclonal / pharmacokinetics
Antibodies, Monoclonal / therapeutic use*
Computer Simulation
Energy Transfer
Humans
Immunoconjugates / pharmacokinetics
Immunoconjugates / therapeutic use*
Iodine Radioisotopes / pharmacokinetics
Iodine Radioisotopes / therapeutic use*
Models, Biological
Monte Carlo Method
Neoplasm, Residual / radiotherapy*
Phantoms, Imaging
Radioimmunotherapy*
Radiotherapy Dosage

Substances

Antibodies, Monoclonal
Immunoconjugates
Iodine Radioisotopes